Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vical, a developer of biopharmaceutical products, and AnGes MG, a biopharmaceutical company, have signed a non-binding letter of intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes.
Subscribe to our email newsletter
AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license, subject to completion of a mutually satisfactory definitive agreement.
AnGes’s experience in working with Vical’s DNA delivery technology within the Japanese regulatory environment positions the company well to pursue further development in Japan based on Vical’s recently announced preliminary Phase I H5N1 pandemic influenza data.